{"id":"NCT03020160","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A","officialTitle":"A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks (Q4W) in Patients With Hemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-30","primaryCompletion":"2017-12-15","completion":"2022-06-29","firstPosted":"2017-01-13","resultsPosted":"2018-12-26","lastUpdate":"2023-01-11"},"enrollment":48,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hemophilia A"],"interventions":[{"type":"DRUG","name":"Emicizumab","otherNames":["Hemlibra","RO5534262","ACE910"]}],"arms":[{"label":"Emicizumab: PK Run-in Cohort","type":"EXPERIMENTAL"},{"label":"Emicizumab: Expansion Cohort","type":"EXPERIMENTAL"}],"summary":"This multicenter, open-label, non-randomized study will assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at a dose of 6 milligrams per kilogram (mg/kg) every 4 weeks in participants with hemophilia A with or without inhibitors against factor VIII (FVIII). The study consists of 2 parts: a pharmacokinetic (PK) run-in part followed by an expansion part.","primaryOutcome":{"measure":"Expansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds","timeFrame":"From Baseline to at least 24 weeks","effectByArm":[{"arm":"Emicizumab: Expansion Cohort","deltaMin":2.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":17,"countries":["United States","Australia","Belgium","Japan","Poland","Spain"]},"refs":{"pmids":["35939785","31003963"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":7},"commonTop":["ARTHRALGIA","HEADACHE","NASOPHARYNGITIS","INJECTION SITE REACTION","BACK PAIN"]}}